Home-monitoring of oral anticoagulation vs. dabigatran: An indirect comparison

Thrombosis and Haemostasis

Volumn 108, Issue 4, 2012, Pages 647-653

  Alonso Coello, Pablo ^a   Zhou, Qi ^b   Guyatt, Gordon ^b  

^a CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Atrial fibrillation; Dabigatran; Oral anticoagulation; Self management

Indexed keywords

ANTIVITAMIN K; DABIGATRAN; WARFARIN;

ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; DEATH; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HOME MONITORING; HOSPITALIZATION; HUMAN; LUNG EMBOLISM; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SELF CARE; SYSTEMATIC REVIEW (TOPIC); THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; DRUG MONITORING; HEMORRHAGE; HUMANS; MONITORING, AMBULATORY; SELF CARE; STROKE; THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 84867250131     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-01-0027     Document Type: Article

References (34)

1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
2. Andersen LV, Vestergaard P, Deichgraeber P, et al. Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis. Heart 2008; 94: 1607-1613.
3. Rietbrock S, Plumb JM, Gallagher AM, et al. How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database. Thromb Haemost 2009; 101: 527-534.
4. Ansell J, Hirsh J, Hylek E, et al; American College of Chest Physicians. Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 160S-198S.
5. Hughes M, Lip GY; Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: 295-304.
6. Gallagher AM, Setakis E, Plumb JM, et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106: 968-977.
7. Christensen TD, Larsen TB. Precision and accuracy of point-of-care testing coagulometers used for self-testing and self-management of oral anticoagulation therapy. J Thromb Haemost 2012; 10: 251-260.
8. Heneghan C, Alonso-Coello P, Garcia-Alamino JM, et al. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006; 367: 404-411.
9. Christensen TD, Johnsen SP, Hjortdal VE, et al. Self-management of oral anticoagulant therapy: a systematic review and meta-analysis. Int J Cardiol 2007; 118: 54-61.
10. Garcia-Alamino JM, Ward AM, Alonso-Coello P, et al. Self-monitoring and selfmanagement of oral anticoagulation. Cochrane Database Syst Rev 2010; 4: CD003839.
11. Bloomfield HE, Krause A, Greer N, et al. Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. Ann Intern Med 2011; 154: 472-482.
12. Christensen TD, Larsen TB, Hjortdal VE. Self-testing and self-management of oral anticoagulation therapy in children. Thromb Haemost 2011; 106: 391-397.
13. Huisman MV, Lip GY, Diener HC, et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838-847.
14. Douxfils J, Mullier F, Robert S, et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107: 985-997.
15. Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators.Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
16. Roskell NS, Lip GY, Noack H, et al. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010; 104: 1106-1115.
17. Guyatt GH, Oxman AD, Vist GE, et al.; GRADE Working Group.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br Med J 2008; 336: 924-926.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
19. Higgins JPT, Thompson SG, Deeks JJ, Altman DG.Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557-560.
20. Review Manager (RevMan) [Computer program]. Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
21. Sun X, Briel M, Walter SD, et al. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. Br Med J 2010; 340: c117.
22. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct andindirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683-691.
23. Wells GA, Sultan SA, Chen L, et al. Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis. Ottawa: Canadian Agencyfor Drugs and Technologies in Health, 2009.
24. Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005; 9: 1-134, iii-iv.
25. Mills EJ, Ghement I, O'Regan C, et al. Estimating the Power of Indirect Comparisons: A Simulation Study. PLoS ONE 2011; 6: e16237.
26. Devereaux PJ, Choi PT, El-Dika S, et al. An observational study found that authors of randomized controlled trials frequently use concealment of randomization and blinding, despite the failure to report these methods. J Clin Epidemiol 2004; 57: 1232-1236.
27. Heneghan C, Ward A, Perera R; Self-Monitoring Trialist Collaboration. Selfmonitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012; 379: 322-334.
28. Regier DA, Sunderji R, Lynd LD, et al. Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy. CMAJ 2006; 174: 1847-1852.
29. Brown A, Wells P, Jaffey J, et al. 34Point-of-care monitoring devices for long-term oral anticoagulation therapy: clinical and cost effectiveness [Technology report no 72]. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2007.
30. Connock M, Stevens C, Fry-Smith A, et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess 2007; 11: iii-iv, ix-66.
31. Medical Advisory Secretariat. Point-of-care international normalized ratio (INR) monitoring devices for patients on long-term oral anticoagulation therapy: an evidence-based analysis. Ontario Health Technology Assessment Series 2009; 9.
32. Shah SV, Gage BF. Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation. Circulation 2011; 123: 2562-2570.
33. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011; 154: 1-11.
34. Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective. Thromb Haemost 2011; 105: 908-919.